AVITA Medical (RCEL) Competitors

AxoGen (NASDAQ:AXGN) and AVITA Medical (NASDAQ:RCEL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

Does the media refer more to AXGN or RCEL?

In the previous week, AxoGen had 6 more articles in the media than AVITA Medical. MarketBeat recorded 10 mentions for AxoGen and 4 mentions for AVITA Medical. AxoGen's average media sentiment score of 0.89 beat AVITA Medical's score of 0.27 indicating that AxoGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
AVITA Medical	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more volatility & risk, AXGN or RCEL?

AxoGen has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, AVITA Medical has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500.

Is AXGN or RCEL more profitable?

AxoGen has a net margin of -7.91% compared to AVITA Medical's net margin of -96.26%. AxoGen's return on equity of -14.91% beat AVITA Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-7.91%	-14.91%	-7.49%
AVITA Medical	-96.26%	-337.91%	-71.50%

Which has better earnings and valuation, AXGN or RCEL?

AxoGen has higher revenue and earnings than AVITA Medical. AxoGen is trading at a lower price-to-earnings ratio than AVITA Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$187.34M	4.50	-$21.72M	-$0.22	-86.32
AVITA Medical	$64.25M	3.83	-$61.85M	-$2.39	-3.92

Do insiders and institutionals have more ownership in AXGN or RCEL?

80.3% of AxoGen shares are owned by institutional investors. Comparatively, 27.7% of AVITA Medical shares are owned by institutional investors. 7.0% of AxoGen shares are owned by company insiders. Comparatively, 1.8% of AVITA Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Do analysts prefer AXGN or RCEL?

AxoGen presently has a consensus price target of $22.60, suggesting a potential upside of 19.01%. AVITA Medical has a consensus price target of $17.25, suggesting a potential upside of 83.90%. Given AVITA Medical's higher probable upside, analysts plainly believe AVITA Medical is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
AVITA Medical	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60

Does the MarketBeat Community favor AXGN or RCEL?

AxoGen received 376 more outperform votes than AVITA Medical when rated by MarketBeat users. Likewise, 72.89% of users gave AxoGen an outperform vote while only 69.83% of users gave AVITA Medical an outperform vote.

Company	Underperform	Outperform
AxoGen	Outperform Votes 457 72.89%	Underperform Votes 170 27.11%
AVITA Medical	Outperform Votes 81 69.83%	Underperform Votes 35 30.17%

Summary

AxoGen beats AVITA Medical on 15 of the 18 factors compared between the two stocks.